Boston OAIC: A Translational Approach to Function Promoting Therapies

波士顿老年美国人独立中心（波士顿OAIC）已经超越了部门， 机构和学科界限，以建立跨学科的研究网络，以促进翻译 研究功能促进疗法（FPTs）-药理学，物理，营养，技术和 行为干预措施，减轻老年人致残性功能限制的负担。在其第一个5 在多年的资助下，波士顿OAIC调查人员出版了255份出版物;获得了8800万美元的赠款; 参与了FPT的开创性随机试验;建立了身体功能和残疾的新方法， 和FPT作用的生物标志物;申请了4项专利，并成立了3家新公司;领导了关于 肌肉减少症和FPT试验设计。波士顿OAIC调查员对OAIC范围的贡献 合作项目，包括STRIDE研究，T试验，肌肉减少症生物标志物倡议， Multi-Mod Hip Fracture Consortium、SARM-PC试验、LIFE和WARGISE试验说明了 以波士顿OAIC为例的多机构研究网络模式的显着力量。 波士顿OAIC将整合19个NIH资助的研究，3个研究教育核心项目，3个试点项目， 和3个发展项目纳入一个跨学科的计划，由领导和 行政核心，研究教育核心（REC），试点和探索性研究核心（PESC），以及3 资源核心（功能评估核心、临床前发现核心、生物统计和数据分析核心）。 我们的REC和PESC候选人包括老年医学和老年学的几位新星，包括3 Beeson 和K奖获得者波士顿OAIC在其对FPT的主题关注及其在整个 从机制阐明，临床前概念验证研究， 生物标志物验证、FPT随机试验的流行病学调查。REC将招募最多的 从哈佛、塔夫茨大学和波士顿大学的大量人才中挑选有前途的明星，并通过说教式的方式培养他们。 教育和指导研究计划。整合将通过PROMOTE计划实现， 包括研究礼宾服务，研究会议，年度务虚会，网站和通讯。与 在其领导层中包括几位哈佛老年病学家，波士顿OAIC现在与 哈佛老年医学和老年学研究社区和项目，包括其T32培训补助金， 哈佛临床转化科学研究所，罗伊巴尔中心，新英格兰老年医学研究 临床教育中心和格伦基金会衰老生物学中心。 OAIC的独特优势包括专注于FPT，强调翻译和商业化， 一大批有才华的年轻研究人员，其在整个翻译研究领域的延伸， 其成员的杰出生产力，强大的机构支持，以及其在发展中的成功 知识产权和公司，并支持一些最重要的FPT随机试验。

The Boston Older Americans Independence Center (Boston OAIC) has transcended the departmental, institutional, and disciplinary boundaries to forge an interdisciplinary research network to foster translational research in function promoting therapies (FPTs) – pharmacologic, physical, nutritional, technological and behavioral interventions that reduce the burden of disabling functional limitations in older adults. In its first 5 years of funding, Boston OAIC investigators published 255 publications; received $88 million in grants; participated in seminal randomized trials of FPTs; established new methods for physical function and disability, and biomarkers of FPT action; filed 4 patents and started 3 new companies; led the consensus panels on sarcopenia and FPT trial design. The contributions of the Boston OAIC investigators to OAIC-wide collaborative projects, including the STRIDE Study, the T Trials, The Sarcopenia Biomarkers Initiative, the Multi-Mod Hip Fracture Consortium, the SARM-PC Trial, the LIFE, and ENERGISE trials illustrate the remarkable power of the multi-institutional research network model exemplified by the Boston OAIC. The Boston OAIC will integrate 19 NIH-funded studies, 3 Research Education Core projects, 3 pilot projects, and 3 developmental projects into an interdisciplinary program that is supported by a Leadership and Administrative Core, a Research Education Core (REC), a Pilot and Exploratory Studies Core (PESC), and 3 resource cores (Function Assessment Core, Preclinical Discovery Core, Biostatistical and Data Analysis Core). Our REC and PESC candidates include several rising stars in Geriatrics and Gerontology, including 3 Beeson and K grant awardees. The Boston OAIC is unique in its thematic focus on FPTs and its positioning across the entire spectrum of translational science from mechanism elucidation, preclinical proof-of-concept studies, biomarker validation, epidemiologic investigation to randomized trials of FPTs. The REC will recruit the most promising stars from a vast reservoir of talent at Harvard, Tufts and BU, and train them through a didactic education and mentored research program. Integration will be achieved by the PROMOTE Program that includes a research concierge service, research meetings, annual retreats, a website and a newsletter. With the inclusion of several Harvard geriatricians in its leadership, the Boston OAIC is now well integrated with the the Harvard Geriatrics and Gerontology research community and programs, including its T32 training grant, Harvard Clinical Translational Science Institute, the Roybal Center, The New England Geriatrics Research Clinical Education Center, and the Glenn Foundation Center for Biology of Aging. Unique strengths of OAIC include its focus on FPTs, emphasis on translation and commercialization, access to a large pool of talented young investigators, its extension across the entire spectrum of translational research, the outstanding productivity of its members, strong institutional support, and its success in developing intellectual property and companies, and supporting some of the most important randomized trials of FPTs.